US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

BriaCell Therapeutics Corp. Warrant

0.0700

0.0000

Volume:- -

Turnover:286.32

Market Cap:- -

PE:- -

High:0.0700

Open:0.0700

Low:0.0700

Close:0.0700

Loading ...

Overview Company News Filings

BRIEF-Briacell Therapeutics Announces Closing Of Public Offering

Briacell Therapeutics Announces Closing of Public Offering

THOMSON REUTERS

BriaCell Therapeutics Announces Closing of Public Offering

BRIACELL THERAP (BCTX) Upgraded to Buy: What Does It Mean for the Stock?

BRIEF-Briacell Therapeutics Prices Public Offering Of 762,500 Shares At $4 Each

Briacell Therapeutics Announces Pricing of Public Offering

THOMSON REUTERS

Briacell Therapeutics Corp - No Toxicity Reported; Patient Remains on Study

THOMSON REUTERS

Briacell Therapeutics Corp - Lung Metastasis Resolved After 2 Months of Bria-Ots Treatment

THOMSON REUTERS

Briacell Announces Resolution of Lung Metastasis in First Patient Treated With Bria-Ots™

THOMSON REUTERS

Briacell Therapeutics Corp - First Patient Result Supports Bria-Ots Immunotherapy Approach

THOMSON REUTERS

BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025

BriaCell Announces Proposed Effective Date of Share Consolidation

Insider Purchases Worth US$5.52m See Losses As BriaCell Therapeutics Market Value Drops To CA$40m

Simply Wall St.

BRIEF-Briacell Therapeutics Announces Closing Of $5.5 Million Public Offering

Briacell Therapeutics Announces Closing of $5.5 Million Public Offering

THOMSON REUTERS

Briacell Therapeutics Announces Pricing of $5.5 Million Public Offering

THOMSON REUTERS

BriaCell Therapeutics Announces Pricing of $5.5 Million Public Offering

Briacell Therapeutics Announces Proposed Public Offering

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BCTXW/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BCTXW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCTXW\",,,,,undefined,":{"symbol":"BCTXW","market":"US","secType":"STK","nameCN":"BriaCell Therapeutics Corp. Warrant","latestPrice":0.07,"timestamp":1749488169933,"preClose":0.07,"halted":0,"volume":0,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":0,"latestTime":"06-09 12:56:09 EDT","open":0.07,"high":0.07,"low":0.07,"amount":286.3215037,"amplitude":0,"askPrice":0.099,"askSize":100,"bidPrice":0.063,"bidSize":100,"shortable":0,"etf":0,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1749499200000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":0.07,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCTXW\",,,,,undefined,":{"symbol":"BCTXW","floatShares":0,"roa":"-158.14%","roe":"-536.81%","lyrEps":0,"shares":0,"dividePrice":0,"high":0.07,"amplitude":0,"preClose":0.07,"low":0.07,"week52Low":0.0238,"pbRate":"0.00","week52High":0.7,"institutionHeld":0,"latestPrice":0.07,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":0.07,"prevYearClose":0.2895,"prevWeekClose":0.07,"prevMonthClose":0.09,"prevQuarterClose":0.1019,"fiveDayClose":0.106,"twentyDayClose":0.065,"sixtyDayClose":0.1046},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BCTXW\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2509251801","title":"BRIEF-Briacell Therapeutics Announces Closing Of Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2509251801","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509251801?lang=en_us&edition=fundamental","pubTime":"2025-02-06 05:19","pubTimestamp":1738790391,"startTime":"0","endTime":"0","summary":"BRIEF-Briacell Therapeutics Announces Closing Of Public OfferingFeb 5 (Reuters) - Briacell Therapeutics Corp BCT.TO:BRIACELL THERAPEUTICS ANNOUNCES CLOSING OF PUBLIC OFFERINGSource text: ID:nGNX8SntvZFurther company coverage: BCT.TO ((reuters.briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250205:nTUA207VPW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCTXW"],"gpt_icon":0},{"id":"2509025930","title":"Briacell Therapeutics Announces Closing of Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2509025930","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509025930?lang=en_us&edition=fundamental","pubTime":"2025-02-06 05:05","pubTimestamp":1738789528,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250205:nTUA207VPW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCTXW"],"gpt_icon":0},{"id":"2509516882","title":"BriaCell Therapeutics Announces Closing of Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2509516882","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509516882?lang=en_us&edition=fundamental","pubTime":"2025-02-06 05:05","pubTimestamp":1738789500,"startTime":"0","endTime":"0","summary":"PHILADELPHIA and VANCOUVER, British Columbia, Feb. 05, 2025  -- BriaCell Therapeutics Corp.   , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its previously announced best-efforts public offering of 762,500 common shares at a public offering price of $4.00 per share. The Company received gross proceeds from the offering, before deducting the placement agent’s fees and other offering expenses, of $3.05 million. The Company relied upon the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as Nasdaq.The Company intends to use the net proceeds from the offering for working capital requirements, general corporate purposes, and the advancement of business objectives.ThinkEquity acted as sole placement agent for the offering.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/briacell-therapeutics-announces-closing-public-210500067.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BCTX","BK4139","LENZ","BCTXW"],"gpt_icon":0},{"id":"2509123098","title":"BRIACELL THERAP (BCTX) Upgraded to Buy: What Does It Mean for the Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2509123098","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509123098?lang=en_us&edition=fundamental","pubTime":"2025-02-06 01:00","pubTimestamp":1738774812,"startTime":"0","endTime":"0","summary":"BRIACELL THERAP  could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 . This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time.Therefore, the Zacks rating upgrade for BRIACELL THERAP basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/briacell-therap-bctx-upgraded-buy-170012297.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BCTXW","BCTX"],"gpt_icon":0},{"id":"2508398108","title":"BRIEF-Briacell Therapeutics Prices Public Offering Of 762,500 Shares At $4 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2508398108","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508398108?lang=en_us&edition=fundamental","pubTime":"2025-02-04 09:04","pubTimestamp":1738631058,"startTime":"0","endTime":"0","summary":"BRIEF-Briacell Therapeutics Prices Public Offering Of 762,500 Shares At $4 EachFeb 3 (Reuters) - Briacell Therapeutics Corp BCT.TO:BRIACELL THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERINGBRIACELL TH","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250204:nTUA2SKJGJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCTXW"],"gpt_icon":0},{"id":"2508517023","title":"Briacell Therapeutics Announces Pricing of Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2508517023","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508517023?lang=en_us&edition=fundamental","pubTime":"2025-02-04 08:59","pubTimestamp":1738630769,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250204:nTUA2SKJGJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCTXW"],"gpt_icon":0},{"id":"2508711759","title":"Briacell Therapeutics Corp - No Toxicity Reported; Patient Remains on Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2508711759","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508711759?lang=en_us&edition=fundamental","pubTime":"2025-02-03 20:30","pubTimestamp":1738585802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250203:nTUA927TZZ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCTXW"],"gpt_icon":0},{"id":"2508175461","title":"Briacell Therapeutics Corp - Lung Metastasis Resolved After 2 Months of Bria-Ots Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2508175461","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508175461?lang=en_us&edition=fundamental","pubTime":"2025-02-03 20:30","pubTimestamp":1738585802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250203:nTUA927TZZ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCTXW"],"gpt_icon":0},{"id":"2508117590","title":"Briacell Announces Resolution of Lung Metastasis in First Patient Treated With Bria-Ots™","url":"https://stock-news.laohu8.com/highlight/detail?id=2508117590","media":"THOMSON REUTERS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508117590?lang=en_us&edition=fundamental","pubTime":"2025-02-03 20:30","pubTimestamp":1738585802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250203:nTUA927TZZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCTXW"],"gpt_icon":0},{"id":"2508117578","title":"Briacell Therapeutics Corp - First Patient Result Supports Bria-Ots Immunotherapy Approach","url":"https://stock-news.laohu8.com/highlight/detail?id=2508117578","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508117578?lang=en_us&edition=fundamental","pubTime":"2025-02-03 20:30","pubTimestamp":1738585802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250203:nTUA927TZZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCTXW"],"gpt_icon":0},{"id":"2500276591","title":"BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2500276591","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500276591?lang=en_us&edition=fundamental","pubTime":"2025-01-04 06:05","pubTimestamp":1735941900,"startTime":"0","endTime":"0","summary":"PHILADELPHIA and VANCOUVER, British Columbia, Jan. 03, 2025  -- BriaCell Therapeutics Corp.   , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Company’s Annual General Meeting of Shareholders , which was originally scheduled to be held on Thursday, January 23, 2025, has been rescheduled. The Meeting is now scheduled to be held on Wednesday, February 5, 2025, at 9:00 a.m.  at Suite 3400, One First Canadian Place, Toronto, ON, M5X 1A4. The record date for the Meeting, December 9, 2024, is unchanged and applies to the postponed Meeting. The Meeting has been postponed due to delays stemming from the disruption in postal service in Canada, and to provide further time to solicit proxies from the Company’s shareholders.Registered shareholders are shareholders who hold their shares directly in the Company, and not through a brokerage account or depository company. Registered shareholders can call Computershare Shareholder","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/briacell-announces-rescheduling-annual-general-220500914.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BCTX","BK4581","BK4561","BK4585","BCTXW","BK4590","ET","BK4144","BK4588"],"gpt_icon":0},{"id":"2500127656","title":"BriaCell Announces Proposed Effective Date of Share Consolidation","url":"https://stock-news.laohu8.com/highlight/detail?id=2500127656","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500127656?lang=en_us&edition=fundamental","pubTime":"2025-01-04 06:05","pubTimestamp":1735941900,"startTime":"0","endTime":"0","summary":"PHILADELPHIA and VANCOUVER, British Columbia, Jan. 03, 2025  -- BriaCell Therapeutics Corp.   , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care announced today that the Company’s board of directors has approved the consolidation  of the Company’s issued and outstanding common shares  on the basis of one  post-Consolidation Common Share for every fifteen  pre-Consolidation Common Shares. The Consolidation is being implemented to ensure that the Company continues to comply with the listing requirements of The Nasdaq Capital Market .It is anticipated that upon completion of the Consolidation, the post-Consolidation Common Shares will continue to trade on the TSX under the symbol “BCT” and on the Nasdaq under the symbol “BCTX”, under a new CUSIP number: 107930208.BriaCell is a clinical-stage biotechnology company that develops novel immunot","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/briacell-announces-proposed-effective-date-220500710.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BCTX","MNQmain","BCTXW","QID","TSYW.SI","NQmain","BK4139",".IXIC","NVIW.SI","TQQQ","SQQQ","USJW.SI","USAW.SI","PSQ","QLD"],"gpt_icon":1},{"id":"2492787231","title":"Insider Purchases Worth US$5.52m See Losses As BriaCell Therapeutics Market Value Drops To CA$40m","url":"https://stock-news.laohu8.com/highlight/detail?id=2492787231","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492787231?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:05","pubTimestamp":1734613551,"startTime":"0","endTime":"0","summary":"Insiders who bought US$5.52m worth of BriaCell Therapeutics Corp.'s  stock at an average buy price of US$2.99 over the last year may be disappointed by the recent 45% decrease in the stock. This is not good as insiders invest based on expectations that their money will appreciate over time. However, as a result of recent losses, their original investment is now worth only US$1.60m.Although we don't think shareholders should simply follow insider transactions, logic dictates you should pay some attention to whether insiders are buying or selling shares.BriaCell Therapeutics Insider Transactions Over The Last Year. What Might The Insider Transactions At BriaCell Therapeutics Tell Us?The recent insider purchase is heartening. We also take confidence from the longer term picture of insider transactions. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. When combined with notable insider ownership, these factors suggest BriaCell The","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/insider-purchases-worth-us-5-130551585.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CA","BK4139","BCTX","LENZ","BCTXW"],"gpt_icon":0},{"id":"2491835445","title":"BRIEF-Briacell Therapeutics Announces Closing Of $5.5 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2491835445","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491835445?lang=en_us&edition=fundamental","pubTime":"2024-12-14 05:06","pubTimestamp":1734123974,"startTime":"0","endTime":"0","summary":"BRIEF-Briacell Therapeutics Announces Closing Of $5.5 Million Public OfferingDec 13 (Reuters) - Briacell Therapeutics Corp BCT.TO:BRIACELL THERAPEUTICS ANNOUNCES CLOSING OF $5.5 MILLION PUBLIC OFFERINGSource text: nGNX6392KDFurther company coverage: BCT.TO ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241213:nTUA2PFCQD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCTXW"],"gpt_icon":0},{"id":"2491583341","title":"Briacell Therapeutics Announces Closing of $5.5 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2491583341","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491583341?lang=en_us&edition=fundamental","pubTime":"2024-12-14 05:05","pubTimestamp":1734123900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241213:nTUA2PFCQD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCTXW"],"gpt_icon":0},{"id":"2490882698","title":"Briacell Therapeutics Announces Pricing of $5.5 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2490882698","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490882698?lang=en_us&edition=fundamental","pubTime":"2024-12-12 12:54","pubTimestamp":1733979282,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241212:nTUA8YBNKH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCTXW"],"gpt_icon":0},{"id":"2490260628","title":"BriaCell Therapeutics Announces Pricing of $5.5 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2490260628","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490260628?lang=en_us&edition=fundamental","pubTime":"2024-12-12 12:54","pubTimestamp":1733979240,"startTime":"0","endTime":"0","summary":"PHILADELPHIA and Vancouver, British Columbia, Dec. 11, 2024  -- BriaCell Therapeutics Corp.   , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the pricing of an underwritten public offering of 7,400,000 common shares and warrants to purchase 7,400,000 common shares at a combined public offering price of $0.75 per share and associated warrant. The warrants will have an exercise price of $0.9375 per share and will be immediately exercisable upon issuance for a period of five years following the date of issuance. All of the common shares and associated warrants in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting underwriters discounts and other offering expenses, are expected to be approximately $5.55 million. The offering is expected to close on December 13, 2024, subject to satisfaction of customary closing conditions. The Company is relying upon the exemption set","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Fapu7tR5DxauNKta6Slkew--~B/aD0zODY7dz00NDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/17b9221138faf4e9b9308828981b6076","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Fapu7tR5DxauNKta6Slkew--~B/aD0zODY7dz00NDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/17b9221138faf4e9b9308828981b6076"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/briacell-therapeutics-announces-pricing-5-045400611.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BCTX","BCTXW","LENZ","BK4139"],"gpt_icon":0},{"id":"2490818321","title":"Briacell Therapeutics Announces Proposed Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2490818321","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490818321?lang=en_us&edition=fundamental","pubTime":"2024-12-12 05:05","pubTimestamp":1733951100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241211:nTUA8YYSW8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCTXW"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":38,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BCTXW\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BCTXW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BCTXW\",market:\"US\",delay:false,,,undefined,":{}}}